In the past 2 years, an emerging body of research has focused on a novel transcriptional pathway involved in the cardiac hypertrophic response. Ever since its introduction, the significance of the calcineurin-NFAT module has been subject of controversy. The aim of this review is to provide both an update on the current status of knowledge and discuss the remaining issues regarding the involvement of calcineurin in hypertrophic heart disease. To this end, the molecular biology of calcineurin and its direct downstream transcriptional effector NFAT are discussed in the context of the genetic studies that established the existence of this signaling paradigm in the heart. The pharmacological mode-of-action and specificity of the calcineurin inhibitors cyclosporine A (CsA) and FK506 is dicussed, as well as their inherent limitations to study the biology of calcineurin. A critical interpretation is given on studies aimed at analyzing the role of calcineurin in cardiac hypertrophy using systemic immunosuppression. To eliminate the controversy surrounding CsA / FK506 usage, recent studies employed genetic inhibitory strategies for calcineurin, which confirm the pivotal role for this signal transduction pathway in the ventricular hypertrophy response. Finally, unresolved issues concerning the role of calcineurin in cardiac pathobiology are discussed based upon the information available, including its controversial role in cardiomyocyte viability, the reciprocal relationship between 21 myocyte Ca homeostasis and calcineurin activity and the relative importance of calcineurin in relation to other hypertrophic signaling cascades.
Molecular biology of calcineurin
vated T-cells (NFAT), which shuttled between cytoplasmic 21 and nuclear components under influence of a Ca signal. The calcineurin-NFAT pathway was one of the first Subsequently, nuclear NFAT import was defined to be signaling paradigms that provided molecular insight how regulated by dephosphorylation steps catalyzed by the extracellular signals travel from the cell membrane into the phosphatase calcineurin, which in its turn was subject to 21 nucleus. The precise components of the pathway were regulation by Ca -calmodulin binding [1] [2] [3] . Finally, defined by working backwards from the T-lymphocyte calcineurin was identified as the cellular target of the nucleus to the cell membrane. The regulatory region in the immunosuppressive agents CsA and FK506 [1,2]. interleukin-2 (IL-2) gene was found to be under control of Calcineurin itself is a heterodimer composed of two a transcriptional factor designated nuclear factor of actidistinct subunits, designated calcineurin A, a 58-59 kDa subunit which contains the catalytic site of the enzyme, and a small |19 kDa calcineurin B subunit which contains the Ca -binding regulatory domain of the holoenzyme. 2. First evidence for a role of calcineurin in cardiac Three different mammalian genes, designated a, b and g, hypertrophy encode calcineurin A, and share substantial homology in the domain encoding the catalytic site. Of these isoforms, Molkentin and colleagues first established the existence calcineurin Ag displays a testis-restricted expression patof a myocardial calcineurin-NFAT module [11] . Using a tern, while calcineurin Aa and Ab exist in an overlapping yeast-two-hybrid screening of interacting factors for the fashion in multiple tissues, including the heart. Multiple cardiac embryonic transcription factor GATA-4, a specific alternative splice isoforms of calcineurin Aa and Ab have interaction was observed between zinc finger domains of been reported [4] . The smaller calcineurin B subunit is GATA-4 with the DNA binding domain of NFATc4 encoded by two genes, each having alternative splice (NFAT3). Since interaction between NFATc4 and GATAisoforms [5] . Only mutant mice lacking calcineurin Aa 4 drove synergistic activation of a brain natriuretic peptide have been created and these animals display a subtle defect (BNP) promoter-reporter construct, a specific role for in the antigen-specific T-cell response [6] , accumulation of NFATc4 activation and hypertrophic gene induction was a hyperphosphorylated form of tau in the mossy fibers of suggestive. (Fig. 1) [11] the hippocampus, accompanied by cytoskeletal changes
In line with this hypothesis, CsA (calcineurin inhibition) and altered synaptic plasticity in the central nervous prevented the hypertrophic growth response of cultured system [7, 8] . The phenotype of the calcineurin Aa knockcardiomyocytes in response to humoral factors as angiotenout is surprising in that it does not reveal the full scale of sin II (AngII) and phenylephrine (PE) [11] . To elucidate phenotypic characteristics associated with CsA or FK506 the functional significance of the calcineurin-NFATc4 administration, suggesting functional redundancy between pathway in vivo, several lines of transgenic mice were the calcineurin Aa and Ab isoforms. The creation and generated containing either truncated activated mutants of phenotypic characterization of genetic mouse models NFATc4 or the calcineurin Aa subunit specifically in the mutant for either calcineurin Ab or calcineurin B will be heart. Persistent calcineurin activation was sufficient to instrumental for resolving these issues and efforts along promote a hypertrophic response in 11 separate TG this line are in progress (Bueno and Molkentin, Unfounder lines, varying from relatively benign forms of published observations).
concentric hypertrophy to severe forms of dilated carTo date, five genes encoding NFAT complexes have diomyopathy and early lethality in low and high copy been identified and designated NFATc1 (NFATc or number TG mice, respectively. Pharmacological inhibition NFAT2), NFATc2 (NFATp or NFAT1), NFATc4 of calcineurin through CsA injections (25 mg / kg per day) (NFAT3), NFATc3 (NFAT4 or NFATx) and NFAT5, of resulted in complete prevention of the pathology [11] . which only the latter appears to be constitutively nuclear NFATc4 TG mice also demonstrated a hypertrophic and not subject to regulation by calcineurin [9, 10] . The myopathy associated with re-expression of fetal genes. As NFATc members share high homology within their DNA a testimony to the specificity of the proposed pathway, binding region, which is related to the Rel domain present
CsA was unable to prevent the morphologic pathology of in the transcription factor NF-kB [9] . NFATc members the NFATc4 TG animals, which express a calcineurintransactivate target genes by interacting with other tranindependent form of the transcription factor [23] . scription factors like c-Maf, activator protein-1 (AP-1), and This initial study was soon followed by one which GATA-4 [11] [12] [13] [14] [15] .
analyzed whether calcineurin may also be involved in the Calcineurin physically interacts with NFATc members ventricular growth response in other animal models of and dephosphorylates serine residues within SP repeats and cardiomyopathy and LV hypertrophy. Accordingly, CsA the serine-rich region. Dephosphorylation of these residues administration prevented hypertrophy in tropomodulin results in the unmasking of two nuclear localization overexpressing mice, a model of dilated cardiomyopathy sequences required for its nuclear import [16] . Nuclear due to sarcomeric disruption [24] [25] [26] [27] . CsA also proved to export, on the other hand, is dependent upon rephosbe effective in TG mice expressing a non-phosphorylatable phorylation of these same residues by glycogen synthase form of myosin light chain 2v (MLC-2v), which display kinase-3b (GSK3b) [17] and the p38 and c-Jun NHhypertrophic cardiomyopathy (HCM) as a result of in-2 terminal protein kinase (JNK) members of the mitogenefficient cross-bridge cycling [24, 28, 29] , and in mice activated protein kinase (MAPK) superfamily [18, 19] . The overexpressing b-tropomyosin, a model of hypertrophic biological significance of the individual NFATc members cardiomyopathy and defective calcium handling is rapidly being elucidated due to the availability of murine [24, 30, 31] . CsA was ineffective, however, in a retinoic models deficient for the single NFATc isoforms [9] . Of acid receptor (RAR) TG driven pathology [24, 32] , indicatinterest to the cardiovascular field, mice lacking NFATc1 ing the possibility that calcineurin activation might act as a die in utero from failure to develop semi lunar cardiac molecular driving force behind some, but not all forms of valves [20, 21] , while the combined disruption of NFATc3 ventricular myopathies. The authors were further able to and NFATc4 results in embryonic lethality due to abberant demonstrate activation of calcineurin enzymatic activity vascular patterning [22] .
concurrent with a 27% increase in indexed heart weight in [12] . In this scheme, Ca / calmodulindependent phosphatase calcineurin is activated by hypertrophic agonists such as Angiotensin II (AngII) or phenylephrine (PE) or by intrinsic defects, which 21 trigger an increase in intracellular Ca . Upon activation, calcineurin dephosphorylates one single nuclear factor of activated T-cell (NFATc) target, which translocates to the nucleus upon activation. NFATc4 (NFAT3) physically associates with the transcription factor GATA-4 to synergistically activate gene transcription of hypertrophic genes such as the brain natriuretic peptide gene (BNP).
a rat model of pressure overload created by surgical organ transplantation and in the treatment of diverse constriction of the abdominal aorta. CsA administration immune disorders. These agents produce similar effects on resulted in complete prevention of calcineurin activation signal transduction pathways in T lymphocytes, however, and LV hypertrophy 6 days following coarctation [24] . they do not share similar chemical structure nor do they These two initial studies suggested several novel implireact with the same target. CsA is a neutral, lipophilic and cations for cardiac pathobiology. (1) The existence of a very hydrophobic, cyclic polypeptide of 11 amino acids conservational preservation of a calcineurin-NFATc pathextracted from Tolypocladium inflatum Gams. Following way in the myocardium, such as defined earlier in T oral or intravenous administration, CsA distributes rapidly lymphocytes; (2) the potential of this transcriptional between blood cells and plasma with an apparent large pathway to activate a fetal gene expression profile convolume of distribution of 4 to 8 l / kg [33] . CsA accumusistent with LV hypertrophy (Fig. 1) ; and (3) pharmacolates in erythrocytes (50-60%) and in leukocytes (10-logical inhibition of (transgenically driven levels) of 20%), the remainder of the drug is bound to plasma activated calcineurin prevents the histopathology resulting lipoproteins. Tissue drug concentrations depend on actual from its activation. These initial studies immediately cyclophilin and lipid content. CsA is metabolized preevoked questions related to the significance of this novel dominantly in the liver by cytochrome P-450IIIA enzymes pathway in view of the complexity and hierarchy of the to more than 30 metabolites. These metabolites do not multitude of hypertrophic signaling pathways known to contribute significantly to the immunosuppressive effects govern cardiac hypertrophy. To address these issues the of CsA since the most active ones only retain 10-20% of vast majority of these studies, unfortunately, made use of the activity of the parent compound. CsA does not cross the pharmacological inhibitors of calcineurin. The inconthe blood-brain barrier, but it crosses the placenta and it sistent outcome of these studies ignited controversy regardcan be detected in amniotic fluid and fetal blood. The ing the requirement of this pathway in the LV hypertrophic elimination half-life of CsA has been estimated of approxiresponse. mately 6 h [33] . FK506 is a macrolide antibiotic extracted from Streptomyces tsukubaensis. FK506 can be administered orally or intravenously and its elimination half-life is approximately 3. Pharmacological inhibitors of calcineurin 20 h. It is extensively metabolized in the liver since less than 1% of the drug is excreted unchanged. FK506 is Csa (Sandimmune) and FK506 or tacrolimus (Prograf) approximately 100 times more potent than CsA in its are the most important immunosuppressive agents used in calcineurin inhibitory characteristics.
The mechanism of action of these two immunosuppresorgans besides the heart muscle (e.g. neural tissue, smooth sive agents has been investigated extensively in immune muscle, kidney), which may influence the outcome of cells. CsA and FK506 bind with high affinity to the hypertrophy studies. ubiquitous cytosolic peptidyl-propyl isomerases cyclophilin and FK506-binding protein-12 (FKBP12), respectively. The complex of CsA-cyclophilin or FK506-FKBP12 associates with calcineurin and inhibits its phos-4. CsA and FK506: evidence in support of a role for phatase activity as well as its interaction with a variety of calcineurin in hypertrophy substrates. CsA and FK506 also inhibit the peptidyl-propyl isomerase activity of cyclophilin and FKBP12, but this Endothelin-1 (ET-1) is an established humoral factor effect is not involved in the immunosuppressive mechathat induces cardiac hypertrophy. ET-1 was reported to nism of these drugs since CsA analogues with no effect on increase the activity of CaMKII and calcineurin in cultured T-cell activation are still able to block the peptidyl-propyl cardiac myocytes and pretreatment with KN62 (CaMK isomerase activity.
inhibitor) or CsA strongly suppressed ET-1-induced inIt is generally accepted that calcineurin inhibition by creases in phenylalanine uptake and in cell size. PharmacoCsA and FK506 blocks the dephosphorylation and sublogic inhibition of calmodulin, CaMK or calcineurin or sequent nuclear translocation of the NFATc transcription overexpression of dominant-negative mutants of CaMKII factors [34, 35] . However, novel, calcineurin-independent and calcineurin strongly suppressed hypertrophic gene mechanisms of action for CsA and FK506 have recently activation [46] . Similarly, leukemia inhibitory factor (LIF), been proposed. It has been hypothesized that part of the a hypertrophic cytokine employing gp130 receptors for immunosuppressive effects of CsA are mediated through transmembrane signaling, enhanced both calcineurin and TGFb1, a cytokine with immunosuppressive effects in CaMK activities. KN62 and CsA administration signifidiverse cells and tissues [36, 37] . However, this is still a cantly reduced LIF-induced hypertrophy and fetal gene 21 matter of controversy since other studies have failed to expression, suggesting a crucial role for these Ca -actishow an induction of TGF-b1 production during CsA vated pathways in LIF-mediated cardiomyocyte growth treatment [38] . This issue could potentially be of interest to [47] (Table 1) . the current topic in view of the recent demonstration that CsA demonstrated to be highly effective in selective TGFb-activated kinase (TAK1) activation can tropomodulin overexpressing mice, in mice expressing a result in a cardiomyopathic phenotype in mice [39] . CsA non-phosphorylatable form of myosin light chain 2v was also found to inhibit the activation of some family (MLC-2v) and in mice overexpressing b-tropomyosin [24] . members of the mitogen-activated protein kinases (MAPK) An additional genetic model of hypertrophy, the Gqa in different cell types, although this may still be an indirect overexpressing mouse, was found to be partially sensitive response to calcineurin inhibition [40, 41] . Chronic CsA to comparable doses of CsA [48] . administration produces changes in the properties of the Shimoyama and colleagues analyzed the effectiveness of 21 sarcoplasmatic reticulum (SR) Ca -release channel [42] FK506 in a rat model of pressure overload hypertrophy. A and in isolated guinea-pig cardiomyocytes alterations in drug dosage-effect preceded this study to minimize toxic 21 the kinetics of L-type Ca channels [43] . side-effects on parameters as blood pressure, cardiac The ryanodine receptor (RyR2) is a multiprotein comhemodynamics, and operative mortality. Accordingly, a plex including several phosphatases, kinases, achoring dosage of 1 mg / kg per day FK506 injected intramuscularproteins and FKBP12.6. Altered RyR2 channel function ly was found to have negligible side-effects, yet still has been postulated to play a role in cardiomyopathy, since inhibited LV calcineurin activation. A 3-week treatment hyperphosphorylation of the complex was observed in regimen on abdominal aortic constricted animals was human heart failure biopsies, which results in dissociation associated with a near complete prevention of the increase of FKBP12.6 from its cognate receptor. These events result in (indexed) heart size, fibrosis formation, and hyper- 21 in increased Ca sensitivity for activation, elevated trophic marker gene expression [49] . 21 channel open probability, and impaired myocyte Ca Using the same rat model, Lim and colleagues demonhomeostasis [44] . Genetic ablation of FKBP12 resulted in strated that a 14-day CsA regimen resulted in a dosesevere septum defects and dilated cardiomyopathy in mice dependent prevention of the morphologic, histological and [45] . Much less is known about the cardiac biology of the molecular aspects of LV hypertrophy. Although this study target of CsA, the cyclophilin A-D family.
suffered from a moderate post-operative mortality (|25%), Accordingly, it is becoming increasingly clear that CsA mortality was unaffected by the drug. One striking and and FK506 have calcineurin-independent effects in multiclinically relevant finding demonstrated that treatment of ple organs, and do not constitute the optimal tool to test for CsA (20 mg / kg per day) was associated with a regression a potential role of calcineurin in the setting of cardiac of established myocardial hypertrophy resulting from a hypertrophy. If these agents are to be used in a systemic 14-day pressure overload [50] . fashion, precaution should be taken for dosage, mode of Hill and colleagues were able to demonstrate a progresdelivery, and severe extra-cardiac toxicity on major target sive and reproducible hypertrophic response following a LIF, Leukemia Inhibitory Factor; PE, phenylephrine; AngII, angiotensin II; ET-1, endothelin-1; HD, hypertrophy development; AC, aortic constriction; ca, constitutively active; RAR, retinoic acid receptor; TG, transgenic; CnA, calcineurin; DS, Dahl-salt sensitive; SHR, spontaneously hypertensive rat; CsA, cyclosporine A; NA, not applicable; NR, not reported; HF, heart failure; OCM, obstructive cardiomyopathy; AM, accelerated mortality; WL, weight loss; DPS, decreased blood pressure; PI, pulmonary infection; FHC, familial hypertrophic cardiomyopathy; MLC-2v*, non-phosphorylatable myosin light chain-2v. a FK506 induces hypertrophy when used in combination with rapamyicin.
5-week period thoracic aortic banding protocol in mice mg / kg per day) over a 6-week period of severe hyperten-(45% increase in HW/ BW). A relatively high dose of CsA sion. In fact, cardiac enzymatic calcineurin activity was resulted in a near complete blockade of this response elevated at any time point examined in this hypertensive (Table 1 ). The authors found no evidence of deleterious model. FK506 also prevented fibrosis deposition and effects of CsA on myocardial hemodynamics, the transexpression of certain fetal-type cardiac genes. Sakata et al. stenotic pressure gradient, weight gain, physical activity or demonstrated LV blockade and prevention to heart failure mortality [51] . Mice with renovascular hypertension, development in the same model when FK506 (1 mg / kg created by a two kidney one clip method, also demonper day) was administered early (from 8 weeks), but no strated substantial LV calcineurin activation and CsA attenuation of heart failure remodeling when administered prevented hypertrophy in this model (Table 1) [52] . late in life (from 17 weeks) [53] . Using the Dahl salt-sensitive rat model, which develops Using TG rats harboring both the human renin and a rapid onset hypertension and both pressure and volume angiotensin genes, Mervaala et al. investigated CsA effecoverload hypertrophy, Shimoyama and colleagues demontiveness to protect against Ang II-induced myocardial and strated a substantial reduction in indexed left ventricular renal damage. In their model, CsA completely prevented weight using only very low doses of FK506 (0.1 and 0.01 cardiovascular death, decreased 24-h albuminuria by 90%, lowered systolic blood pressure by 35 mmHg, and unfortunately, calcineurin activity assays were not proprotected against the development of cardiac hypertrophy vided [58] . Ding and colleagues investigated CsA effec- [54] .
tiveness in a murine model of ascending aortic constriction Calcineurin activation may also play a role in distinct [59] . Morphometric analyses of hearts subjected to this hypertrophic stimuli [55] . Following 10 weeks of volvery severe form of pressure overload revealed no statistiuntary exercise training to evoke a physiological adaptive cal differences between non-treated and CsA-treated, hypertrophy response in rats, indexed LV weight and LV banded animals. In fact, calcineurin activity assays recalcineurin activity were increased by 20% and 2.5 fold, vealed a lower enzymatic activity following pressure respectively, and CsA was effective in preventing both overload compared to sham operated animals. Given this, parameters [55] . Post-infarction failure is usually associone would not expect a significant impact from further ated with a strong volume overload stimulus. Rats subjectCsA administration (calcineurin inhibition), yet the authors ed to chronic myocardial infarction (MI) and administered reported development of heart failure by drug treatment CsA over a 14-day post-MI recovery period demonstrated [59] . a significant attenuation of cardiac hypertrophy and aMeguro et al. found a substantial prevention of LV skeletal actin gene induction. However, the inhibition of hypertrophy by CsA treatment in transverse aortic conhypertrophy led to an increased incidence of LV dilation stricted mice over a period of 3 weeks. However, a and reduced hemodynamic performance, suggesting acdisproportionate number of premature deaths in the CsA celeration of the heart failure development in this model treated group was observed, all within the first 7 days of [56] . the study and accompanied by pleural efflusion. Invasive LV hemodynamic analysis revealed a significant lower ascending as well as abdominal systolic aortic pressure in 5. CsA and FK506: no correlation between the presence of comparable trans stenotic pressure gracalcineurin and cardiac hypertrophy dient, suggesting both an intrinsic myocardial depressive and a distal blood pressure lowering effect by CsA. The Boluyt and colleagues demonstrated significant activaauthors concluded that inhibition of LV hypertrophy might S6K tion of 70-kDa S6 kinase (P70 ) following phenylepbe of detriment to the heart, and could accelerate dehrine-stimulation, and rapamycin pretreatment prevented compensation and heart failure [60] . this effect [57] . Rapamycin mediates its effects through Luo and colleagues investigated a similar pressure specific binding to the intracellular immunophilin FKBP.
overload model in the rat by constriction of the abdominal Since FK506 and rapamycin both bind FKBP and act aorta as initially employed by multiple groups [24, 49, 50 ] mutually antagonistic, the authors used FK506 at a 10-fold and randomized their groups to receive different doses of molar excess to competitively reverse the anti-hyperCsA or FK506 [61] . No effect of CsA or FK506 on the trophic, rapamycin-mediated effects. This study implicates development of LV hypertrophy was observed, but a that FK506 may have both anti-hypertrophic (calcineurin significant increase in mortality was evident with increasinhibition) as well as pro-hypertrophic properties, albeit ing dosages of CsA or FK506. In fact, the highest FK506 that latter effects only play a role at excess concentrations, dose (4 mg / kg per day) was associated with 90% mortality and emphasizes the need for correct CsA or FK506 dosage [61] . use to study calcineurin biology.
Zhang and colleagues demonstrated that 6 week CsA In the initial report of Sussman and coworkers, the RAR treatment (5 mg / kg per day) was associated with a overexpressing TG model failed to morphologically resignificant elevation of blood pressure in the spontaneously spond to CsA [24] . This model was created to study the hypertensive rat (SHR) model, but this additive blood function of excessive retinoid signaling during cardiac pressure increase was not associated with increased heart morphogenesis, and resulted in severe heart failure in weight [62] . To avoid interpretative complications due to neonates and juvenile mice when a consititutively activated the genetic component of the SHR model, the authors next RAR was driven to the embryonic ventricle by the bturned to normotensive rats to address the effect of CsA on MyHC promoter. Interestingly, postnatal ventricular expressure overload induced hypertrophy. Two weeks of pression of the same receptor (driven by the a-MyHC
CsA treatment resulted in a 28% increase in indexed LV promoter) did not result in cardiac pathology, suggesting a weights in abdominal aorta constricted rats compared to a critical role for retinoid signaling during developmental 38% increase in vehicle-treated, banded animals, a differstages of ventriculogenesis. Nevertheless, the failure of the ence that was not found to be statistical significant. Four RAR model to respond to systemic immunosuppressive weeks of aortic banding resulted in an increase of 46% in therapy suggests that retinoid signaling acts independently vehicle treated animals, while CsA treated banded animals from calcineurin during cardiomorphogenesis.
demonstrated an increase of 27 and 22% at CsA dosages of Muller and coworkers found that CsA administration of 10 and 20 mg / kg per day, respectively. Again, the 25 mg / kg twice daily did not attenuate cardiac hyperdifference was not indicated as statistically significant, trophy in mice with transverse aortic constriction, but, even though CsA appeared to have dose-dependent effects on the development of LV hypertrophy. This particular lower whole body upper limit tolerance in rats with the study was also associated with a substantial post-operative Dahl-Iwai background [67] . This contrasts with dosages mortality, ranging from 33 to 67%, and a reduction in of up to 4 mg / kg per day FK506 used in Sprague-Dawley pressure gradients at 4 weeks, most notably in CsA treated rats (40-to 400-fold excess vs. Shimoyama et al.
[67]) groups [62] .
which, not surprisingly, resulted in up to 90% mortality in Hayashida and coworkers observed increased LV calpressure-overloaded animals. Clearly, the vast variations in cineurin activity in hypertensive hypertrophied Dahl-Issei genetic background and drug dosage must have influenced rat strain, but not during the later congestive heart failure the interpretation of calcineurin involvement in cardiac phase. However, a CsA regimen started at 11 weeks of age hypertrophy. did not prevent LV hypertrophy, nor heart failure developCareful inspection further suggests some degree of ment [63] .
variance associated with surgical procedure, peri-operative Finally, in a murine model of familial hypertrophic milieu and route of drug administration. A number of cardiomyopathy (FHC) bearing a knock-in missense mutastudies have reported a high degree of drug-associated 403 / 1 tion in the cardiac myosin heavy chain (aMyHC ) premature mortality, up to 90% in drug administered [64] , both CsA and FK506 resulted in accentuated LV animals, an effect which might have preselected interhypertrophy and worsening of pathology [65] . Pre-treatindividual variations. In fact, careful inspection suggests an ment with diltiazem (I antagonist) prevented the exagginverse relation between high mortality and drug-effective- [53, 67] , while another reported cineurin involvement, implicating that other signaling no effectiveness when they started CsA injections at 11 modules may take over in relative importance to the weeks of age [63] . Luo and colleagues reported high expense of calcineurin. Indeed, it has been postulated that mortality and no CsA effectiveness in rats administered the calcineurin inhibition effectively blocks Ang II-mediated drug in the drinking water [61] . The majority of studies, cardiac hypertrophy, such as that developing in response to however, have injected CsA or FK506 subcutaneously abdominal aortic banding or following reduced renal (often twice daily) due to its low solubility in aqueous perfusion in renovascular hypertension. In support of this solutions and limited half-life. view, all reports involving models with AngII activation A final issue concerns the phenotypic interpretation (abdominal aortic constriction [49, 50] ; renin-angiotensin following drug administration. Meguro et al. reported high TG rat [54] ; two-kidney-one-clip [52] ) reported a higher mortality in their CsA banded animal groups, interpreted degree of CsA / FK506 effectiveness (Table 1) . This view as development of heart failure since a disproportionate must be an oversimplification, since constriction of the number of animals displayed pleural effusion upon autopsy aortic arch (transverse aortic constriction) does not activate [60] . It is unlikely, however, that heart failure was the true the renin-angiotensin system [66] , yet one report still cause of death. Only a 28 and 16% decrease in LV demonstrated near complete prevention of hypertrophy by dP/dt and LV ejection fraction in CsA-treated, banded max CsA administration [51] (Table 1) . vs. vehicle-treated, banded animals was observed, respecGenetic variability between the animals and their sentively [60] . A more plausible explanation for their observasitivity to CsA / FK506 may play an underestimated role tions would be enhanced susceptibility to pleural infection and coincides with substantial variability in drug dosage.
in treated animals [67] due to the systemic immunoTo date, Sprague-Dawley rats, Wistar rats and FVB / N suppressive therapy [67]. mice exhibited a relatively higher degree of drug tolerance Conclusively, the vast majority of studies, regardless of than Dahl-Iwai rats and C57BL / 6 mice ( Table 1) . The their qualitative outcome, were hindered to some degree by most striking example of drug tolerance and strain depenintra-and extracardiac side effects of the drugs. Latter dency is provided by the studies of Shimoyama and notion underscores the problematic situation of using CsA colleagues [49, 67] , where Wistar rats tolerated 1 mg / kg or FK506 as experimental devices, virtually excludes their per day FK506 [49] , while the same group found a 10-fold potential as future treatment options for patients with hypertrophic heart disease, and motivated some research (ANF) expression (Fig. 2) . The same non-competitive groups to find alternative experimental strategies to elucicalcineurin inhibitors were recently overexpressed in a date the myocardial (patho)physiological role of calcardiac-restricted manner in mice. DCain and DAKAP79 cineurin.
TG animals demonstrated stable transgene expression in the cardiac compartment, reduced cardiac calcineurin activity and a significant attenuation of hypertrophy in response to catecholamine infusion or pressure overload 7. Genetic inhibition of calcineurin stimuli [78] (Fig. 2) . In the same study, the DCain adenovirus was used for viral-mediated gene transfer of the In recent years, different classes of proteins with calDCain peptide into the adult rat myocardium. Overexprescineurin inhibitory properties have been described. sion of the DCain protein resulted in inhibition of pressure-AKAP79 (for A-kinase anchoring protein) was the first induced calcineurin activation and cardiac hypertrophy ] ] ] ] protein discovered to have calcineurin inhibitory charac- [78] and supports the feasibility to acutely intervene in terstics [68] . AKAP79 acts as a scaffold protein, which reactive hypertrophic signaling using gene therapy apbinds protein kinase A and protein kinase C besides proaches [79] . calcineurin and is thought to anchor multiple classes of
As an alternative approach to inhibit calcineurin, transsignaling modules in the vicinity of substrates to facilitate genic mice expressing a truncated form of human MCIP1 their proper and timed activation [68] . One interesting in a cardiac-selective manner were created. Remarkably, class of calcineurin inhibitors are the products of the unstressed MCIP1 TG animals revealed a 5-10% smaller (Down's syndrome critical region) DSCR1 gene and its heart size, establishing a role for calcineurin in normal, relatives, DSCR2 or ZAK14 [69] . DSRC1 is located on developmental myocardial growth. MCIP1 overexpression human chromosome 21 in the so-called Down's syndrome prevented the massive hypertrophic response, fetal gene critical region. The small gene products of DSCR1 and induction and progression to dilated cardiomyopathy in the DSCR2, designated MCIP1 (for myocyte-enriched calcineurin TG mouse [11] . MCIP1 TG mice demonstrated ] calcineurin interacting protein-1) and MCIP2, respectively, resistance towards cardiac hypertrophy as a result of long-] ] ] are remarkably potent inhibitors of calcineurin activity in term b-adrenergic stimulation and exercise training. Finalstriated muscle [70] . Interestingly, it was demonstrated that ly, myocardial overexpression of a dominant negative (dn) calcineurin activity upregulates the MCIP1 gene product in form of calcineurin provided protection against pressure cardiomyocytes through an intragenic segment in the overload hypertrophy following abdominal aortic banding MCIP1 gene, which includes a dense cluster of consensus in mice [80] . The results from these three reports utilizing NFAT binding sites [71] . MCIP1 may therefore participate four distinct genetic strategies to inhibit calcineurin activiin a negative feedback circuit to diminish potentially ty (DCain, DAKAP79, MCIP1 and dn-calcineurin) make it deleterious effects of unrestrained calcineurin activity in hard to dispute that calcineurin is a required component of striated muscle cell lineages. Two additional classes of hypertrophic signaling following diverse stimuli cellular calcineurin inhibitors are Cain (for calcineurin [78,80, [73, 74] . calcineurin inhibition based approach [78, 80, 81] may still CHP has a high similarity to the calcineurin B subunit and prove to be of significant value. A preferential approach is able to compete with the calcineurin B subunit for would be to identify the critical calcineurin A isoform and binding the calcineurin A subunit [75, 76] .
ablate it in an inducible, ventricular myocyte cell lineageThe identification of specific cellular antagonists of dependent fashion, which would also permit definitive calcineurin have provided an excellent platform to design insight into the temporal aspects of calcineurin inexperimentation that circumvents the issue of drug spevolvement in the distinct stages of heart failure developcificity and whole body toxicity. This strategy was first ment. reported by Taigen and co-workers, who created adenovirStill many other questions remain and concern calal vectors expressing the specific calcineurin binding cineurin's precise pathobiological role in terms of biodomains of the Cain and AKAP79 proteins (designated chemical properties, subcellular localization, crosstalk with DCain and DAKAP, respectively) [77] . AdDCain and other notorious hypertrophic signaling modules, its sugAdDAKAP infection resulted in attenuation of AngII, PE gested role in myocyte viability and its precise contribution and growth factor-induced calcineurin activity, carin the progression of human heart failure. The current diomyocyte hypertrophy, and atrial natriuretic factor status of knowledge of these issues is discussed below. ly, the activity of CaMK, another important Ca / calresulted in increased calcineurin and CamK activities and modulin regulated hypertrophic signal transducer [83] , was nicardipine and verapamil pretreatment fully prevented reported to be uniquely sensitive to transient, high amtheir activation, suggesting at least one plausible source of 21 21 plitude Ca fluctuations [82] . The differential response of Ca that activates calcineurin and CaMK. 21 two major Ca / calmodulin-regulated hypertrophic signal Findings in other cell types suggest a reciprocal relation 21 transducers to fundamentally distinct Ca fluctuations between calcineurin on the one hand, and the RyR, IP3 diomyocytes resulted in positive inotropy and increased calcineurin in these and other models of FHC [92] [93] [94] [95] [96] may 21 Ca transients [87] . In addition, adult myocytes derived become helpful in answering these questions. from the calcineurin TG mouse exhibited increased I As a result of these uncertainties regarding momentous Ca,L amplitude and density and shortened time to half decay calcineurin activation, a major experimental problem recompared to wildtype myocytes [88] . Since the total lates to the current assessment of cardiac calcineurin 21 number of L-type Ca channel a1 and b2 subunits was activity. The calcineurin activity assay depends upon unaltered, the increased density of I is due to an inclusion of several phosphatase inhibitors to reduce Ca,L increased fraction of channels that open during the repobackground phosphatase activity and enhance specificity, larization phase. Interestingly, therapeutic doses of CsA since different phosphatases besides calcineurin exist in had no effects on I in wildtype mice, suggesting that cardiac tissue. One required inhibitor (okadaic acid) also
calcineurin indirectly affects L-type Ca channel proppartially inhibits calcineurin activity, leading to an inherent erties. This contrasts observations in the mammalian brain, reduction of output. Furthermore, calcineurin is subject to where calcineurin is the major phosphatase responsible for rapid oxidation in vitro, which underscores the notion that 21 L-type Ca channel inactivation [89] . One plausible calcineurin may be several folds more active in situ explanation for the effects of myocardial calcineurin on the compared with purified protein extracts. Thus, regardless 21 21 profile of myocyte Ca handling may relate to SR Ca whether the complicated technical aspects of the assay are handling. Indeed, Janssen and coworkers demonstrated that performed correctly, the relevance of the information it 21 CsA induces sustained SR Ca leakage from adult rabbit provides is still questionable. Other assays are required to and human ventricular myocytes at therapeutic doses [90] .
objectively monitor instantaneous calcineurin activation in Collectively, calcineurin inhibition may have the potential situ. 21 to alter myocardial intracellular Ca homeostasis and The identification of MCIP1, as part of a self-promoting influence the susceptibility to the occurrence of lethal negative feedback loop of calcineurin biology, may proventricular arrhythmias.
vide an indirect readout of calcineurin activation status. The finding that CsA exacerbated the hypertrophic Before such an assay could be implemented, additional response in a murine FHC model [65] has further compliinvestigation is required to assess whether MCIP1 is 21 cated our understanding of cardiomyocyte Ca homeostaspecifically induced upon calcineurin (NFATc transloca- 21 sis and Ca / calmodulin-regulated signaling in the LV tion) activation or whether it is a more general marker of hypertrophy response [91] . Fatkin and coworkers obhypertrophy status. Another approach could be to use the 21 servecd an increase in Ca transient in wildtype intragenic MCIP1 region, which contains an unusual dense myocytes, and, to a lesser extent, in myocytes from mice cluster of NFAT consensus binding sites [71] , and link this carrying the FHC mutation. Pretreatment with diltiazem, a to reporter genes to create transgenic models that provide a 21 L-type Ca channel blocker, prevented the wosening of constant readout of (myocardial) calcineurin activity. Althe phenotype in mutant mice, suggesting that CsA internatively, transgenic models with multimerized NFATc favourably modulated I properties [65] . Latter interpreconsensus binding sites linked to a reporter output [97] Ca,L tation appears to contrast their finding that CsA subtly may provide an alternative to monitor the temporal dy-
increased the Ca transient of aMyHC myocytes. namics of calcineurin activation during the progression of Moreover, Yatani and coworkers [88] failed to observe a LV hypertrophy. 21 response of CsA on L-type Ca channel kinetics in Studies on calcineurin involvement in failing human wildtype myocytes, and Janssen and coworkers observed a hearts further underscored the complex pathobiology of 21 reduction of the Ca transient in human failing trabeculae calcineurin. Human hypertrophic biopsies revealed that following CsA administration [90] .
calcineurin activity (as measured by the enzymatic assay) Nevertheless, latter study poses the interesting question correlated well with absolute calcineurin Ab protein levels whether blockade of calcineurin is of detriment to FHC-(as measured by immunoblot analyses) [98] . It appears that associated LV hypertrophy yet effective to reduce acquired in addition to an acute increase in enzymatic activity of 21 forms of LV hypertrophy and dilated cardiomyopathies. pre-existing protein (Ca activation), activity may also be The finding that CsA and FK506 proved to be highly subject to positive feedback mechanisms at the transcripeffective in rescuing the cardiac phenotype of tional and / or translational level. Therefore, future caltropomodulin or MLC-2v transgenic mice [24] , while cineurin assays may simply become based upon assess-
exacerbating the phenotype of aMyHC animals sugment of absolute myocardial calcineurin Ab protein levels. gests several possibilities. Alterations at the sarcomere may either induce cardiomyopathy through fundamentally 21 distinct alterations in intracellular Ca homeostasis, and / 9. Calcineurin and cardiomyocyte viability or these studies might have suffered from the short-comings of the particular animal model investigated, and / or Mitochondria occupy an unusual large fraction of inthe findings are related to calcineurin-unrelated effects of tracellular volume within adult cardiomyocytes. Multiple the drugs investigated. Genetic approaches to inhibit death signals impinge upon the mitochondrial membrane potential, resulting in hallmark apoptotic events such as protects the heart from apoptotic death, depending upon loss of mitochondrial matrix components and activation of the actual death signal and (sub)cellular context. The caspases. Since cardiomyocytes are limited in their ability precise molecular mechanisms behind the anti-apoptotic to enter the cell cylce reentry, cummulative loss of single properties of calcineurin are most complex and could well cardiomyocytes is regarded as a contributing factor in the be associated with the the initiation of the hypertrophic genesis of human heart failure [99] . Given this, remarkably response itself [104] . few studies have assessed whether calcineurin activity may influence muscle cell viability.
To test whether programmed cell death may contribute 10. Calcineurin and (human) heart failure to the rapid transition from hypertrophy to overt heart failure in the calcineurin TG mice, calcineurin adenoviral
The vast majority of reports to date have remained infected cardiomyocytes were tested for their viability.
focussed upon assessing the involvement of calcineurin on Morphological analyses and TUNEL assays provided the initiation and early progression phase of LV hyperevidence that calcineurin activtion afforded protection trophy. Although justified in view of the intimate relationagainst 2-deoxyglucose and staurosporine-mediated apopship between LV hypertrophy and progression of congestosis. Moreover, endogenous calcineurin activation through tive heart failure, remarkably few studies have directly PE stimulation [77] resulted in substantial protected caraddressed the more clinically relevant question whether diomyocytes from apoptosis, and this effect could be altering the balance of calcineurin activity directly alters antagonized by targeted inhibition of calcineurin by the pathogenesis of (experimentally induced) cardiac failadenoviral DCain gene transfer [77] . The mode of protecure. tion was found to be partially associated with NFATc Current experimental efforts have been limited to the translocation and protein kinase B (Akt) activation. In demonstration that CsA prevents morphological remodelsupport of these findings in vitro, it was demonstrated that ing in the tropomodulin or MLC-2v overexpressing mice massively hypertrophic hearts from adult calcineurin TG with dilated cardiomyopathy [26, 27] , and hemodynamic animals displayed a remarkable level of resistance against recordings of the rescued phenotypes are still lacking. In ischemia / reperfusion-induced TUNEL laddering. Conlight of recent evidence that CsA has direct cardio-depresversely, CsA treatment did not render cardiomyocytes sive actions on rabbit and human cardiomyocytes [90] , an more vulnerable towards programmed cell death, not even assessment whether genetic calcineurin inhibition per se in the apoptosis prone Gqa-overexpressing, carhas negative inotropic / lusitropic effects in these and other diomyopathic mouse model, suggesting that endogenous valuable murine models of severe heart failure [105] [106] [107] [108] [109] . calcineurin activation promotes cardiomyocyte viability A recent study established the activation of calcineurin [100] . These findings were largely supported by a recent in biopsies of patients with hypertrophy secondary to report from Kakita and colleagues, who were able to hypertension ('compensatory hypertrophy') and patients demonstrate that ET-1-mediated protection of carwith heart failure secondary to coronary artery disease or diomyocyte apoptosis requires calcineurin activation, since idiopathic DCM. One interesting feature of the study is CsA and FK506 negated ET-1-induced protection against that both increased specific calcineurin activation and apoptotic cell death and expression of the anti-apoptotic calcineurin Ab protein was evident in patients with factor Bcl-2 [101] .
'compensatory hypertrophy', while calcineurin activation In contrast, Saito and co-workers demonstrated a 3-fold in the failing hearts seemed to be due to only a relative increase in calcineurin enzymatic activity following isoincrease in protein content. These findings were supported proteronol exposure concomitant with DNA fragmentation, by Lim and Molkentin, who reported increased can while CsA and FK506 reversed this effect. TG animals isoform expression in the failing human heart [110] . In expressing a dominant-negative mutant of calcineurin in contrast, Tsao and colleagues reported lower CnAb mRNA the heart were resistant towards isoproteronol-induced levels in human failing hearts, but the probe used was cardiomyocyte apoptosis, suggesting that calcineurin may directed against a minor splice isoform of gene of interest act downstream of catecholamine-induced apoptosis [102] . [111] . Although these findings appear to be in contradiction Due to their substantial extra-cardiac side-effects in with one another, it is known that calcineurin can activate humans, the use of CsA or FK506 as treatment options for opposing pathways that either suppress or induce apoptosis hypertrophic heart disease in patients is doubtful. In fact, in the same cell type [103] . Indeed, Saito et al. reported long term CsA treatment is associated with renal toxicity that myocardial ischemia / reperfusion (oxidative stress) and hypertension, which lead to cardiac hypertrophy in resulted in significantly more cardiomyocyte apoptosis in certain subjects. The concept that CsA or FK506 may have their dominant negative-calcineurin TG model than in direct pro-cardiohypertrophic properties in humans [112] wildtype littermates [102] , supporting the findings of the (and calcineurin inhibition associated with myocardial initial two reports [100] . Conclusively, it seems reasonable growth) is incorrect. More likely, systemic immunoto hypothesize that calcineurin-induced hypertrophy suppression may induce hypertension in select subjects, which influences myocardial growth secondarily. In addimyocardial growth is not regulated by the additive activation, the dose of CsA and FK506 required to prevent tion of signaling modules, but by a more complex mechacardiac hypertrophy in experimental animals studies is nism, involving the activation of multiple (intergrated) approximately 10-fold higher than used to achieve imtransduction pathways (Fig. 3) . munosupression in humans, a phenomenon related to a One aspect that undoubtedly contributes to the integrahigher myocardial calcineurin content, differential tissue tion of cardiac signaling is the interdependence or crosstalk accessibility or the higher metabolic rate of small rodents.
between parallel signaling pathways. We have previously demonstrated that hearts from calcineurin TG mice demonstrated robust JNK MAPK activation, and activation of 11. Integrated signal transduction: calcineurin, several PKC isoforms. Adenoviral expression of calcrosstalk and transcriptional events cineurin resulted in marked hypertrophy in cultured myocytes [87, 100] , and was prevented by JNK or PKC Various reports suggest that multiple signaling networks inhibition [87] . Also, CsA treatment of pressure overplay a role in hypertrophic remodeling [113] . For example, loaded rat hearts prevented PKCa, PKCu and JNK MAPK altering the balance of myocardial RSG4 expression, or activation [87] . Later studies supported this concept of cardiac introduction of a dominant inhibitory G peptide interconnectiveness between calcineurin, PKC and MAPK qa or disruption of the JNK MAPK pathway have been factors [52, 114] , which coincide with the finding that demonstrated to impact on hypertrophic remodeling. How PKCu and calcineurin synergize to activate the JNK is it possible that inhibition of separate signaling networks MAPK pathway in control of the interleukin-2 promoter in can have such dramatic whole organ effects? Clearly, T-cells [115] . Collectively, these studies suggest the among which intrinsic defects of sarcomere function, multiple humoral factors (e.g. AngII, ET-1, LIF, PE), which directly or indirectly (by transient Ca 21 21 release from SR stores through ryanodine sensitive receptors (RyR) or through L-type Ca channels (VLDC) in T-tubuli) elevate free cytosolic Ca . The 21 Ca / calmodulin complex initiates parallel activation of intracellular signaling targets such as Calmodulin activated protein kinase (CaMK) isoforms, calcineurin, myosin light chain kinase (MLCK) or conventional protein kinase C (PKC) isoforms, each of which have been implicated in cardiomyocyte hypertrophy. Calcineurin differentially alters the activation status of certain members of the mitogen-activated protein kinase (MAPK) or PKC superfamilies, most probably as a reinforcement of cellular signaling. Activated calcineurin may recognize up to four nuclear factor of activated T-cell (NFAT) isoforms in the heart and, in addition, increases myocyte-enhancing factor (MEF2) activation status to direct hypertrophic gene expression remodeling. One particularly interesting genetic target of calcineurin is myocyte enriched calcineurin interacting protein-1 (MCIP1), which acts as a myocyte specific calcineurin inhibitor. Similarly, activition of glycogen synthase kinase 3b (GSK3b) counteracts the activation status of NFAT isoforms induced by calcineurin. Calcineurin also positively influences the viability of cardiac muscle cells by effects on the mitochondrial permeability transition (MPT) and anti-apoptotic processes, probably depending upon the actual death signal. Finally, an underrepresented feature of calcineurin function concerns its localization. It has been reported to localize either in the cytosol or nucleus, associated with specialized anchoring proteins [68] , in the vicinity of the sarcoplasmatic reticulum (SR) or close to sarcomeres by its specialized docking protein calsarcin [124] .
at Pennsylvania State University on February 22, 2013 http://cardiovascres.oxfordjournals.org/ Downloaded from existence of a conserved, interconnected, regulatory circuit dence indeed suggests that at least NFATc1 (NFATc) is between calcineurin, PKC and JNK MAPK that controls also present in the ventricular myocyte, can associate with myocardial growth, and it suggests that inhibition of either GATA-4 and responds to calcineurin activation, in a component may abrogate the entire integrated cascade manner analogous to NFATc4. Dominant negative NFATc (Fig. 3) [87] .
approaches that simultaneously abrogate NFATc function Some level of functional diversity and hierarchy among may become useful to circumvent such complications as the multitude of hypertrophic pathways may still be recently demonstrated for T lymphocytes [122] . Alteranticipated. Transgenic lines expressing a constitutively native downstream transcriptional effectors may also be activated mutant of the ERK1 / 2 MAPK-selective activator responsible for the nuclear events downstream of cal-MEK1 display a physiological form of hypertrophy with cineurin. Recent evidence implicates myocyte enhancing increased contractility parameters throughout their comfactor-2 (MEF-2), nuclear factor-kB and Elk-1 [83, 123] . plete life span [116] , while activation of another MAPK Collectively, the present review provided an update on member, ERK5, results in pure eccentric hypertrophy and the role of calcineurin in the pathogenesis of cardiac heart failure [117] . Transgenic overexpression of protein
hypertrophy. An emerging concept indicates that interferkinase CbII (PKCbII) sufficed to result in juvenile lethalience with distinct hypertrophic signaling pathways may ty and cardiac hypertrophy / failure in mice [118] , but its significantly abrogate the LV hypertrophy response [113] . targeted disruption failed to significantly abrogate pressure Therefore, future efforts in this field requires a further overload-induced myocardial growth [119] , suggesting that analyses to identify the key integrated cascades through certain networks are not a required component of the which maladaptive hypertrophic signals are channeled to hypertrophic response.
achieve the ultimate goal of a better treatment of heart Given the above notions and data from contemporary failure. It appears that calcineurin will continue to be the literature, how should we define the role of calcineurin in focus of ongoing research, providing us with a platform to 21 cardiac hypertrophy? Given the massive hypertrophic understand the complexity of Ca / calmodulin signaling response in calcineurin (and CaMK) TG animals, the on cardiac morphology and function. overall success of CsA / FK506 studies to inhibit myocardial growth, and the recent demonstration that genetic calcineurin inhibition strategies successfully abrogate hyAcknowledgements pertrophic growth, it is difficult to dispute that calcineurin (NWO 902-16-275). hypertrophic phase and to a lesser extent in overtly failing patients [98] .
A more fundamental aspect of calcineurin signaling References involves the contribution of downstream transcriptional effectors. NFATc4 (NFAT3) is still viewed upon as the
